The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYN | -84.97% | -99.66% | -67.93% | -100% |
| S&P | +17.53% | +93.66% | +14.13% | +397% |
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 28.9% |
| Market Cap | $3.93M | -3.0% |
| Market Cap / Employee | $0.18M | 0.0% |
| Employees | 22 | 0.0% |
| Net Income | -$13.06M | -57.0% |
| EBITDA | -$3.95M | 9.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.12M | -27.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.22M | 77.1% |
| Short Term Debt | $0.67M | 16.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.57% | -34.3% |
| Return On Invested Capital | -70.37% | -5.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.73M | -36.9% |
| Operating Free Cash Flow | -$4.71M | -36.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.05 | 0.19 | 0.16 | 0.08 | -39.66% |
| Price to Tangible Book Value | 0.24 | 0.77 | 1.79 | -0.47 | -174.85% |
| Enterprise Value to EBITDA | 2.62 | 1.18 | 0.94 | 1.59 | -17.20% |
| Return on Equity | -77.9% | -87.3% | -100.0% | -154.5% | 161.49% |
| Total Debt | $1.74M | $1.57M | $2.86M | $2.89M | 57.98% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
